About (4E)-2-[5-(dioctylamino)pyrazin-2-yl]-4-(2-dioctylazaniumylidene-4-methyl-1,3-oxazol-5-ylidene)-3-oxocyclobuten-1-olate
(4E)-2-[5-(dioctylamino)pyrazin-2-yl]-4-(2-dioctylazaniumylidene-4-methyl-1,3-oxazol-5-ylidene)-3-oxocyclobuten-1-olate (PubChem CID 140591916) has the molecular formula C44H73N5O3
and a molecular weight of 720.10 g/mol. Its IUPAC name is (4E)-2-[5-(dioctylamino)pyrazin-2-yl]-4-(2-dioctylazaniumylidene-4-methyl-1,3-oxazol-5-ylidene)-3-oxocyclobuten-1-olate.
Molecular Properties
| Compound Name | (4E)-2-[5-(dioctylamino)pyrazin-2-yl]-4-(2-dioctylazaniumylidene-4-methyl-1,3-oxazol-5-ylidene)-3-oxocyclobuten-1-olate |
| PubChem CID | 140591916 |
| Molecular Formula | C44H73N5O3 |
| Molecular Weight | 720.10 g/mol |
| Exact Mass | 719.57 |
| IUPAC Name | (4E)-2-[5-(dioctylamino)pyrazin-2-yl]-4-(2-dioctylazaniumylidene-4-methyl-1,3-oxazol-5-ylidene)-3-oxocyclobuten-1-olate |
| SMILES | CCCCCCCCN(CCCCCCCC)c1cnc(C2=C([O-])/C(=C3\OC(=[N+](CCCCCCCC)CCCCCCCC)N=C3C)C2=O)cn1 |
| InChI | InChI=1S/C44H73N5O3/c1-6-10-14-18-22-26-30-48(31-27-23-19-15-11-7-2)38-35-45-37(34-46-38)39-41(50)40(42(39)51)43-36(5)47-44(52-43)49(32-28-24-20-16-12-8-3)33-29-25-21-17-13-9-4/h34-35H,6-33H2,1-5H3 |
| InChIKey | YJMBIEDIFDIEFT-UHFFFAOYSA-N |
| XLogP | 10.49 |
| TPSA | 93.75 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 30 |
| Heavy Atoms | 52 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
| MW ≤ 500 | 720.10 |
| LogP ≤ 5 | 10.49 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 6 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'Aliphatic_long_chain', 'substructure': 'N/A'}, {'alert_name': 'imine_1', 'substructure': 'N/A'}, {'alert_name': 'Michael_acceptor_1', 'substructure': 'N/A'}, {'alert_name': 'quaternary_nitrogen_1', 'substructure': 'N/A'} |
|---|
Analyze (4E)-2-[5-(dioctylamino)pyrazin-2-yl]-4-(2-dioctylazaniumylidene-4-methyl-1,3-oxazol-5-ylidene)-3-oxocyclobuten-1-olate with MolForge
Explore ADMET properties, 3D molecular structure, drug-likeness score, and discover similar compounds using our AI-powered platform.
Launch Full Analysis
Frequently Asked Questions
What is the IUPAC name of (4E)-2-[5-(dioctylamino)pyrazin-2-yl]-4-(2-dioctylazaniumylidene-4-methyl-1,3-oxazol-5-ylidene)-3-oxocyclobuten-1-olate?
The IUPAC name of (4E)-2-[5-(dioctylamino)pyrazin-2-yl]-4-(2-dioctylazaniumylidene-4-methyl-1,3-oxazol-5-ylidene)-3-oxocyclobuten-1-olate (CID 140591916) is (4E)-2-[5-(dioctylamino)pyrazin-2-yl]-4-(2-dioctylazaniumylidene-4-methyl-1,3-oxazol-5-ylidene)-3-oxocyclobuten-1-olate.
What is the SMILES notation for (4E)-2-[5-(dioctylamino)pyrazin-2-yl]-4-(2-dioctylazaniumylidene-4-methyl-1,3-oxazol-5-ylidene)-3-oxocyclobuten-1-olate?
The canonical SMILES for (4E)-2-[5-(dioctylamino)pyrazin-2-yl]-4-(2-dioctylazaniumylidene-4-methyl-1,3-oxazol-5-ylidene)-3-oxocyclobuten-1-olate is CCCCCCCCN(CCCCCCCC)c1cnc(C2=C([O-])/C(=C3\OC(=[N+](CCCCCCCC)CCCCCCCC)N=C3C)C2=O)cn1.
What is the InChIKey of (4E)-2-[5-(dioctylamino)pyrazin-2-yl]-4-(2-dioctylazaniumylidene-4-methyl-1,3-oxazol-5-ylidene)-3-oxocyclobuten-1-olate?
The InChIKey is YJMBIEDIFDIEFT-UHFFFAOYSA-N. The full InChI is InChI=1S/C44H73N5O3/c1-6-10-14-18-22-26-30-48(31-27-23-19-15-11-7-2)38-35-45-37(34-46-38)39-41(50)40(42(39)51)43-36(5)47-44(52-43)49(32-28-24-20-16-12-8-3)33-29-25-21-17-13-9-4/h34-35H,6-33H2,1-5H3.
What are the key properties of (4E)-2-[5-(dioctylamino)pyrazin-2-yl]-4-(2-dioctylazaniumylidene-4-methyl-1,3-oxazol-5-ylidene)-3-oxocyclobuten-1-olate?
(4E)-2-[5-(dioctylamino)pyrazin-2-yl]-4-(2-dioctylazaniumylidene-4-methyl-1,3-oxazol-5-ylidene)-3-oxocyclobuten-1-olate has a molecular weight of 720.10 g/mol, XLogP of 10.49, 30 rotatable bonds, 0 hydrogen bond donors, and 6 hydrogen bond acceptors.
Where does this data come from?
All data for (4E)-2-[5-(dioctylamino)pyrazin-2-yl]-4-(2-dioctylazaniumylidene-4-methyl-1,3-oxazol-5-ylidene)-3-oxocyclobuten-1-olate is sourced from PubChem (CID 140591916), the world's largest open chemistry database maintained by the National Library of Medicine (NIH).